SecurityCBPO / China Biologic Products, Inc. (16938C106)
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Institutional Owners13
Institutional Shares2,810,243 - 10.32%
Common Shares Outstanding27,238,357 shares (as of 2017-06-30)
Institutional Value$ 124,246,000 USD

Institutional Stock Ownership and Shareholders

CBPO / China Biologic Products, Inc. Institutional Ownership

China Biologic Products, Inc. (NASDAQ:CBPO) has 13 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,810,243 shares. Largest shareholders include Smallcap World Fund Inc, BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., BlackRock Group LTD, Standard Life Investments LTD, Manning & Napier Advisors Llc, SPQ Asia Capital Ltd, Veritas Asset Management LLP, Strs Ohio, and R&F Capital Advisors LP.
China Biologic Products, Inc. (NASDAQ:CBPO) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-02-10 13F-HR BlackRock Investment Management, LLC 5,501 2,391 -56.54 685 257 -62.48
2017-05-15 13F-HR R&F Capital Advisors LP 5,258 4,218 -19.78 565 422 -25.31
2017-10-26 13F-HR Acrospire Investment Management LLC 184 0 -100.00 21 0 -100.00
2017-02-10 13F-HR BlackRock Japan Co. Ltd 949 470 -50.47 118 51 -56.78
2018-08-01 13F-HR Veritas Asset Management LLP 0 10,000 0 993
2017-07-20 13F-HR MANNING & NAPIER ADVISORS LLC 82,325 71,755 -12.84 8,241 8,114 -1.54
2017-02-10 13F-HR BlackRock Group LTD 176,262 205,356 16.51 21,941 22,080 0.63
2018-08-06 13F-HR STRS OHIO 7,200 7,200 0.00 583 715 22.64
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 199,382 306,890 53.92 24,819 32,997 32.95
2017-08-14 13F-HR SPQ Asia Capital Ltd 34,324 21,824 -36.42 3,437 2,468 -28.19
2017-02-10 13F-HR BlackRock Fund Advisors 357,390 380,241 6.39 44,488 40,884 -8.10
2017-08-08 13F-HR Airain ltd 3,930 0 -100.00 444 0 -100.00
2017-02-14 SC 13G SMALLCAP WORLD FUND INC 1,664,923
2017-10-26 13F-HR BARING ASSET MANAGEMENT Ltd 166,774 0 -100.00 18,862 0 -100.00
2017-08-10 13F-HR Standard Life Investments LTD 134,229 131,045 -2.37 13,436 14,821 10.31
2018-02-14 13F-HR CORNERSTONE CAPITAL MANAGEMENT HOLDINGS LLC. 363,190 0 -100.00 33,511 0 -100.00
2017-08-08 13F-HR Airain ltd 23,654 3,930 -83.39 2,368 444 -81.25

Related News Stories

Week In Review: 3 More China Biopharmas Planning Hong Kong IPOs

2018-08-26 seekingalpha
Mabpharm Limited, a Taizhou biotech, will IPO in Hong Kong, the eleventh pre-revenue China biopharma to be approved to list there. Mabpharm is developing a portfolio of nine biosimilars, which it hopes will prove to be biobetters. Three of the candidates are in Phase III trials. They were initially discovered by Sinomab, which spun out Mabpharm to develop the drugs, while Sinomab continues to focus on its CRO/CMO operations. (1-0)

China Biologic Products (CBPO) Looks Good: Stock Adds 8.7% in Session

2018-08-21 zacks
China Biologic Products Holdings, Inc. (CBPO - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 2.7% in the past one-month time frame.

China Biologic Products, Inc. (CBPO) Q2 2018 Results - Earnings Call Transcript

2018-08-06 seekingalpha
China Biologic Products, Inc. (NASDAQ:CBPO) Q2 2018 Earnings Conference Call August 6, 2018 7:30 AM ET

Week In Review: CITIC Offers $3.6 Billion To Acquire China Biologic

2018-06-24 seekingalpha
CITIC Capital has submitted a $3.6 billion bid to acquire China Biologic Products (NASDAQ:CBPO), one of China's top five plasma-based biopharmas. The bid, which came at a 34% premium to the previous close, was unsolicited and non-binding. Headquartered in Beijing, CBPO operates plasma-gathering facilities and offers 20 plasma-based products. The offer, priced at $110 per share, represents a P/E ratio of 37 based on the past 12 months, but only 16. (76-2)

Investment firm CITIC Capital offers to buy China Biologic Products

2018-06-18 reuters
(Reuters) - A unit of Chinese investment firm CITIC Capital Holdings Ltd has offered to buy U.S.-listed biotech firm China Biologic Products Holdings Inc (CBPO.O). (8-1)

CUSIP: 16938C106